Justus Bingham
Principal Pharmacometrician, CSO & Co-founder
Justus Bingham has more than years of experience in the pharmaceutical industry, specifically in clinical pharmacology and pharmacokinetics and is an expert in pharmacometrics modeling and simulation. At CV Therapeutics he managed all PK/PD for the company's pipeline across all phases of development. Mr. Bingham has a broad range of experience in both small and large molecule pharmaceutical research and development. He has held positions at Eli Lilly, CV Therapeutics and Gilead. Twelve years ago Mr. Bingham transitioned to consulting and long term contracting focusing on leveraging quantitative modeling and simulation to speed up pharmaceutical development. Of significant note, Mr. Bingham has created new methodologies in statistical bootstrapping that are quicker and more accurate than standard techniques allowing them to be deployed more widely when processing time is a bottleneck to use. Mr. Bingham has significant experience as a consultant, having been the Senior Expert Consultant for modeling and simulation at Genentech, and M&S Expert Consultant for PK/PD at Certara. As an independent consultant he has provided his expertise to many companies such as Pfizer, Eli Lilly, Rosa, Navitas, Vitaeris, Gilead, STC Biologics, BASF, Dexport, Kineta Inc., University of Illinois at Champaign-Urbana super computing center and Deloitte Consulting. He has provided pharmacokinetic/pharmacodynamic, clinical pharmacology, study design, modeling and simulation, regulatory, statistics, and financial modeling assistance to clients.
Mr. Bingham's work focuses on advancing the processes of modeling and simulation toward broader use within the research and development pipeline; in particular, with an emphasis on quantitative development. He lives in the San Francisco Bay area with his family and 3 overgrown and overfed dogs.
Grant Hogeland
Principal Pharmacometrician, CEO & Co-founder
Dr. Hogeland has over years of experience in Clinical Pharmacology and Pharmacometrics with a broad background in PK/PD data analysis, modeling and simulation. Dr. Hogeland has extensive experience in planning, executing, and analyzing nonclinical and clinical pharmacology studies across numerous therapeutic areas from nonclinical IND enabling studies through Phase 1 to late stage and post-marketing studies. Dr. Hogeland has worked across the drug development landscape of small molecule compounds to biologics, as well as a broad range of administration routes including topical, inhaled, oral, and various injectable routes.
Dr. Hogeland has held Pharmacokineticist, Clinical Pharmacology, Pharmacometrician and Executive positions in the pharma industry. In these positions, he has been responsible for defining the comprehensive clinical pharmacology development path and strategies. Provided scientific support for the design, analysis, reporting, and presentation of sophisticated PK/PD modeling and simulation initiatives, including population PK/PD analyses for both preclinical and early and late phase clinical trials. He has provided clinical pharmacology/PKPD support for regulatory documents, agency interactions, and business development efforts. He has authored, reviewed, and contributed to many PK(/PD) study reports, clinical study reports, clinical protocols, analysis plans, meeting briefing packets, investigator brochures, and IND annual reports. Dr. Hogeland has extensive knowledge of a variety of software used in support of pharmacometric modeling including NONMEM®, PhoenixTM WinNonlin®, and the S/R programming language and RStudio IDE for dataset creation, statistical analysis, simulation, and visualization.
Dr. Hogeland received a BA in Chemistry at Nebraska Wesleyan University and his PharmD from the University of Nebraska Medical Center (UNMC) -- College of Pharmacy. Following graduation, he went on to complete a Pharmacy Practice Residency at the University of Iowa Hospitals and Clinics and then completed a 2-year Clinical Pharmacokinetics/Pharmacodynamics Post-Doctoral Fellowship in the Division of Pharmacotherapy and Experimental Therapeutics at the University of North Carolina at Chapel Hill.
Seth Berry
Principal Pharmacometrician & CTO
Dr. Berry has over years of experience in the pharmaceutical industry, specializing in the clinical pharmacology and pharmacometrics fields. Dr. Berry's extensive background in Pharmacokinetic / Pharmacodynamic (PK/PD) data analysis has focused on performing population PK/PD modeling and clinical trial simulation methodologies to optimize dose selection and study design. His work can be found in numerous therapeutic areas, with various types of formulations, from pre-clinical thru Phase 1 to 3, NDA submissions, and post-marketing activities.
He is also involved in the development of precision dosing applications for individualizing pharmacotherapy, building high performance computing solutions, and writing R packages for non-linear mixed effects modeling. Dr. Berry has authored numerous publications and presentations in the pharmacometrics discipline, while also mentoring students, fellows, and colleagues through various workshops and training seminars.
Dr. Berry obtained his PharmD from the University of Missouri-Kansas City, School of Pharmacy, completed a 2-year Post-Doctoral Pharmacokinetic / Pharmacodynamics (PK/PD) Fellowship with the University of North Carolina, and a 2-year Pharmacometrics Fellowship with the Center for Drug Development Science at Georgetown University, before spending nearly 18 years working in IQVIA's (formerly Quintiles) Clinical Pharmacology / Pharmacokinetics and Innovation Groups.
Isabelle Kuan
Pharmacometrician
Dr. Kuan received her BPharm and PhD in Clinical Pharmacology and Pharmacometrics from the University of Otago (New Zealand). Following completion of her doctoral studies she completed a two-year post-doctoral pharmacometrics fellowship with Certara-Monash University where she was involved in providing pharmacometric consulting services, focused on pharmacokinetic-pharmacodynamic modeling and simulation methodologies.
She was first exposed to pharmacometrics during her undergraduate studies, where her BPharm(Hons) program research project involved the use of modeling and simulation techniques to answer the question *“Are conventional methods for measuring isotopic glomerular filtration rate really the gold standard?”*. Her PhD research project investigated *“The dosing of metformin in the setting of impaired kidney function”*. During her doctoral studies, Dr. Kuan supervised BPharm undergraduate students through pharmacokinetic research projects, involving the application of population pharmacokinetic modelling, dose-response investigations and statistical analysis to inform drug dosing.
Dr. Kuan is interested in dose-individualization - understanding why patients respond differently to drug therapy and how we can optimize their clinical outcomes. Outside of work and away from her computer you can find Isabelle chasing after her toddler and dog!
Angie Dangler
Associate Pharmacometrician
Angela (Angie) Dangler is an Associate Pharmacometrician who joined Momentum Metrix, LLC, in the fall of 2022 after completing her Master of Science in Pharmacometrics through the University of Maryland – Baltimore. She is excited to be working with leaders in pharmacometrics consulting and analysis services and is eager to establish herself as a valuable asset in the non-compartmental analysis and population pharmacokinetic / pharmacodynamics (PK/PD) modeling and simulation arenas.
Angie has over 16 years of experience as a board certified, residency trained clinical pharmacist, with a focus in medication safety, regulatory, and quality improvement initiatives. In addition to a MS in Pharmacometrics, she received a BS in Biochemistry from the University of Nebraska-Lincoln and her PharmD from the University of Nebraska Medical Center.
Outside of work, Angie is a dedicated spouse and parent to three amazing kiddos and a relentless houseplant killer in Denver, CO. She enjoys refining her culinary skills in the kitchen, live music, and the pursuit of perfect pull-ups and PRs at CrossFit.
Svetomir Hitov
Clinical Data Scientist
Svetomir Hitov is a Clinical Data Scientist with a strong passion for automating and enhancing clinical analysis and reporting. His educational background includes a bachelor’s degree in molecular biology, a master's degree in Nano biotechnology, with coursework concentrated in bioinformatics and biostatistics.
In recent years, his focus has primarily been on Real-World Data (RWD) in the fields of cancer and rare genetic diseases. Notably, he successfully formed and co-led a small team dedicated to R development. During this time, Svetomir developed custom R packages and conducted retrospective database studies to answer pressing scientific gaps in drug development.
Svetomir is well-versed in various data standards, such as ADaM and OMOP, for both clinical and genomics data. Furthermore, his interests also include optimizing programming practices and promoting the use of modern languages like R, Julia, and Python, as well as advanced tools and systems for clinical and biological data analysis.